Skip to main content
SpringerLink
Log in

Effect of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a summary

  • Chapter
The Carnitine System

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 162))

  • 75 Accesses

Abstract

Aberrations in carnitine biochemistry often lead to cardiovascular disorders. At the level of the heart, the abnormalities are probably due to the toxic effects of long-chain acylcarnitines [1]. Table 1 shows the effect of L-carnitine on patients with such deficiencies. Data from the literature indicate clearly the benefit of L-carnitine treatment for primary and secondary muscular and systemic carnitine deficiency linked to inborn errors of metabolism [2, 3]. It is one of the 30 drugs for life-threatening illnesses approved by the Food and Drug Administration in the 1980s [10].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Corr PB, Creer MH, Yamada KA, Saffitz JE, Sobel BE. Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest 1989; 83: 927–936.

    Article  PubMed  CAS  Google Scholar 

  2. Treem WR, Stanley CA, Finegold DN, Hale DE, Coates PM. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. N Engl J Med 1988; 319: 1331–1336.

    Article  PubMed  CAS  Google Scholar 

  3. Anonymous. Carnitine deficiency. Lancet 1990; 335: 631–633 (Editorial).

    Article  Google Scholar 

  4. Marin-Garcia J, Goldenthal MJ. Cardiomyopathy and abnormal mitochondrial function. Cardiovasc Res 1994; 28: 456–463.

    Article  PubMed  CAS  Google Scholar 

  5. Vockley J. The changing face of disorders of fatty acid oxidation. Mayo Clin Proc 1994; 69: 249–257.

    Article  PubMed  CAS  Google Scholar 

  6. Stanley CA, Hale DE, Berry GT, Deleeuw S, Boxer J, Bonnefont J-P. Brief report: A deficiency of carnitine-acylcarnitine translocase in the inner mitochondrial membrane. N Engl J Med 1992; 327: 19–23.

    Article  PubMed  CAS  Google Scholar 

  7. Pande SV, Brivet M, Slama A, Demaugre F, Aufrant C, Saudubray J-M. Carnitine-acylcar-nitine translocase deficiency with severe hypoglycemia and auriculo ventricular block. Translocase assay in permeabilized fibroblasts. J Clin Invest 1993; 91: 1247–1252.

    Article  PubMed  CAS  Google Scholar 

  8. Demaugre F, Bonnefont J-P, Collonna M, Cepanec C, Leroux J-P, Saudubray J-M. Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies. J Clin Invest 1991; 87: 859–864.

    Article  PubMed  CAS  Google Scholar 

  9. Taroni F, Verderio E, Fiorucci S et al. Molecular characterization of inherited carnitine palmitoyltransferase II deficiency. Proc Natl AcadSciUSA 1992; 89: 8429–8433.

    Article  PubMed  CAS  Google Scholar 

  10. Anonymous. Drug development for life-threatening illnesses is taking under five years on average, FDA says; early NDAs before study completion are key. FDC Reports 1989; 51: 7–9.

    Google Scholar 

  11. Rizzon P, Biasco G, Di Biase M et al. High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects. Eur Heart J 1989; 10: 502–508.

    PubMed  CAS  Google Scholar 

  12. Tripp ME, Shug AL. Plasma carnitine concentrations in cardiomyopathy patients. Biochem Med 1984; 32: 199–206.

    Article  PubMed  CAS  Google Scholar 

  13. Conte A, Hess OM, Maire R et al. Klinische Bedeutung des Serumcarnitines für den Verlauf und die Prognose der dilatativen Kardiomyopathie. Z Kardiol 1987; 76: 15–24.

    PubMed  CAS  Google Scholar 

  14. Regitz V, Shug AL, Fleck E. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 1990; 65: 755–760.

    Article  PubMed  CAS  Google Scholar 

  15. Pierpont ME, Judd D, Goldenberg IF, Ring WS, Olivari MT, Pierpont GL. Myocardial carnitine in end-stage congestive heart failure. Am J Cardiol 1989; 64: 56–60.

    Article  PubMed  CAS  Google Scholar 

  16. Regitz V, Bossaller C, Strasser R, Müller M, Shug AL, Fleck E. Metabolie alterations in end-stage and less severe heart failure — myocardial carnitine decrease. J Clin Chem Clin Biochem 1990; 28: 611–617.

    PubMed  CAS  Google Scholar 

  17. Masumura Y, Kobayashi A, Yamazaki N. Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure. Jpn Circ J 1990; 54: 1471–1476.

    Article  PubMed  CAS  Google Scholar 

  18. Spagnoli LG, Corsi M, Villaschi S, Palmieri G, Maccari F. Myocardial carnitine deficiency in acute myocardial infarction. Lancet 1982; 1: 1419–14120.

    Article  PubMed  CAS  Google Scholar 

  19. Hiatt WR, Nawaz D, Brass EP. Carnitine metabolism during exercise in patients with peripheral vascular disease. J Appl Physiol 1987; 62: 2383–2387.

    PubMed  CAS  Google Scholar 

  20. Brevetti G, Angelini C, Rosa M et al. Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation 1991; 84: 1490–1495.

    Article  PubMed  CAS  Google Scholar 

  21. Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders. Clin Ter 1991; 13: 2–21.

    CAS  Google Scholar 

  22. Iliceto S, D’Ambrosio G, Scrutinio D, Marangelli V, Boni L, Rizzon P. A digital network for long-distance echocardiographic image and data transmission in clinical trials: The CEDIM study experience. J Am Soc Echocardiogr 1993; 6: 583–592.

    PubMed  CAS  Google Scholar 

  23. Kamikawa T, Suzuki Y, Kobayashi A et al. Effects of L-carnitine on exercise tolerance in patients with stable angina pectoris. Jpn Heart J 1984; 25: 587–597.

    Article  PubMed  CAS  Google Scholar 

  24. Ferrari R, Cucchini F, Visioli O. The metabolic effects of L-carnitine in angina pectoris. Int J Cardiol 1984; 5: 213–216.

    Article  PubMed  CAS  Google Scholar 

  25. Cherchi A, Lai C, Angelino F et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol 1985; 23: 569–572.

    PubMed  CAS  Google Scholar 

  26. Canale C, Terrachini V, Biagini A et al. Bicycle ergometer and echocardiographic study in healthy subjects and patients with angina pectoris after administration of L-carnitine: semiautomatic computerized analysis of M-mode tracing. Int J Clin Pharmacol Ther Toxicol 1988; 26: 221–224.

    PubMed  CAS  Google Scholar 

  27. Sotobata I, Noda S, Hayashi H et al. Clinical evaluation of the effects of levocarnitine chloride (LC-80) on exercise tolerance in stable angina pectoris by the serial multistage treadmill exercise testing: a multicenter, double-blind study. Jpn J Clin Pharmacol Ther 1989; 20: 607–618.

    Article  Google Scholar 

  28. Fujiwara M, Nakano T, Tamoto S et al. Effect of L-carnitine in patients with ischemic heart disease. J Cardiol 1991; 21: 493–504 (In Japanese).

    PubMed  CAS  Google Scholar 

  29. Fernandez C, Proto C. La L-carnitina nel trattamento deH’ischemia miocardica cronica. Analisi dei risultati di tre studi multicentrici e rassegna bibliografica. Clin Ter 1992; 140: 353–377.

    PubMed  CAS  Google Scholar 

  30. Cacciatore L, Cerio R, Ciarimboli M et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp Clin Res 1991; 17: 225–235.

    PubMed  CAS  Google Scholar 

  31. Kobayashi A, Masumura Y, Yamazaki N. L-Carnitine treatment for congestive heart failure — Experimental and clinical study. Jpn Circ J 1992; 56: 86–94.

    Article  PubMed  CAS  Google Scholar 

  32. Palazzuoli V, Modillo S, Faglia S, D’Aprile N, Camporeale A, Gennari C. Valutazione dell’attività antiaritmica della L-carnitina e del propafenone nella cardiopatia ischemica. Clin Ter 1993; 142: 155–159.

    PubMed  CAS  Google Scholar 

  33. Di Biase M, Biasco G, Rizzon P. Ruolo della terapia metabolica nell’infarto miocardico. Cardiologia 1991; 36(Suppl 1): 389–392.

    PubMed  Google Scholar 

  34. Davini P, Bigalli A, Lamanna F, Boem A. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res 1992; 18: 355–365.

    PubMed  CAS  Google Scholar 

  35. Martina B, Zuber M, Weiss P, Burkart F, Ritz R. Antiarrhythmische Behandlung mit L-Carnitin beim akuten Myokardinfarkt. Schweiz Med Wochenschr 1992; 122: 1352–1355.

    PubMed  CAS  Google Scholar 

  36. Brevetti G, Chiariello M, Ferulano G et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988; 77: 767–773.

    Article  PubMed  CAS  Google Scholar 

  37. Brevetti G, Attisano T, Perna S, Rossini A, Policicchio A, Corsi M. Effect of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, crossover study. Angiology 1989; 40: 857–862.

    Article  PubMed  CAS  Google Scholar 

  38. Brevetti G, Perna S, Sabbà C et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J 1992; 13: 251–255.

    PubMed  CAS  Google Scholar 

  39. Ghidini O, Azzurro M, Vita G, Sartori G. Evaluation of the therapeutic efficacy of L-carnitine in congestive heart failure. Int J Clin Pharmacol Ther Toxicol 1988; 26: 217–220.

    PubMed  CAS  Google Scholar 

  40. Pucciarelli G, Mastursi M, Latte S et al. Effetti clinici ed emodinamici della propionil-L-carnitina nel trattamento dello scompenso cardiaco congestizio. Clin Ter 1992; 141: 379–384.

    PubMed  CAS  Google Scholar 

  41. De Leonardis V, Neri B, Bacalli S, Cinelli P. Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data. Int J Clin Pharmacol Res 1985; 5: 137–142.

    PubMed  Google Scholar 

  42. Demeyere R, Lormans P, Weidler B, Minten J, Van Aken H, Flameng W. Cardioprotective effects of carnitine in extensive aortocoronary bypass grafting: a double-blind, randomized, placebo-controlled clinical trial. Anesth Analg 1990; 71: 520–528.

    Article  PubMed  CAS  Google Scholar 

  43. Garg R, Yusuf S. Current and ongoing randomized trials in heart failure and left ventricular dysfunction. J Am Coll Cardiol 1993; 22(Suppl A): 194A–197A.

    Article  PubMed  CAS  Google Scholar 

  44. Chiddo A, Gaglione A, Musci S et al. Hemodynamic study of intravenous propionyl-L-carnitine in patients with ischemic heart disease and normal left ventricular function. Car-diovasc Drugs Ther 1991; 5(Suppl 1): 107–111.

    Article  Google Scholar 

  45. Cherchi A, Lai C, Onnis E et al. Propionyl carnitine in stable effort angina. Cardiovasc Drugs Ther 1990; 4: 481–486.

    Article  PubMed  CAS  Google Scholar 

  46. La Gioia R, Scrutinio D, Mangini SG et al. Propionyl-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. Int J Cardiol 1992; 34: 167–172.

    Article  Google Scholar 

  47. Bartels GL, Remme WJ, Pillay M et al. Acute improvement of cardiac function with intravenous L-propionylcarnitine in humans. J Cardiovasc Pharmacol 1992; 20: 157–164.

    PubMed  CAS  Google Scholar 

  48. Coto V, D’Alessandro L, Grattarola G et al. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. Drugs Exp Clin Res 1992; 18: 29–36.

    PubMed  CAS  Google Scholar 

  49. Greco AV, Mingrone G, Bianchi M, Ghirlanda G. Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double blind trial versus placebo. Drugs Exp Clin Res 1992; 18: 69–80.

    PubMed  CAS  Google Scholar 

  50. Mancini M, Rengo F, Lingetti M, Sorrentino GP, Nolfe G. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforsch 1992; 42: 1101–1104.

    PubMed  CAS  Google Scholar 

  51. Caponnetto S, Canale C, Masperone MA, Terracchini V, Valentini G, Brunelli C. Efficacy of L-propionylcarnitine treatment in patients with left ventricular dysfunction. Eur Heart J 1994; 15: 1267–1273.

    PubMed  CAS  Google Scholar 

  52. Di Lisa F, Menabö R, Siliprandi N. L-Propionyl-carnitine protection of mitochondria in ischemic rat hearts. Mol Cell Biochem 1989; 88: 169–173.

    Article  PubMed  Google Scholar 

  53. Tassani V, Cattapan F, Magnanimi L, Peschechera A. Anaplerotic effect of propionyl carnitine in rat heart mitochondria. Biochem Biophys Res Commun 1994; 199: 949–953.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiochemical Laboratory, Thoraxcenter Ee2371, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands

    Dr. Jan Willem De Jong

Authors
  1. Dr. Jan Willem De Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberto Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Thoraxcenter, Erasmus University, Rotterdam, The Netherlands

    J. W. De Jong

  2. Cattedra di Cardiologia, Università degli Studi di Brescia, Fondazione Clinica del Lavoro di Pavia, Gussago/Brescia, Italy

    R. Ferrari

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

De Jong, J.W., Ferrari, R. (1995). Effect of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a summary. In: De Jong, J.W., Ferrari, R. (eds) The Carnitine System. Developments in Cardiovascular Medicine, vol 162. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0275-9_27

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-0275-9_27

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-4122-5

  • Online ISBN: 978-94-011-0275-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation